Entest Biomedical Stock Performance

ETNI Stock  USD 0.0002  0.00  0.00%   
The firm shows a Beta (market volatility) of 1.99, which means a somewhat significant risk relative to the market. As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Entest Biomedical will likely underperform. At this point, Entest Biomedical has a negative expected return of -1.38%. Please make sure to confirm Entest Biomedical's treynor ratio and day median price , to decide if Entest Biomedical performance from the past will be repeated at some point in the near future.

Risk-Adjusted Performance

Weakest

 
Weak
 
Strong
Over the last 90 days Entest Biomedical has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in March 2026. The recent confusion may also be a sign of long-lasting up-swing for the firm traders. ...more
Begin Period Cash Flow267.00
Total Cashflows From Investing Activities1937.00
Free Cash Flow-3959.00
  

Entest Biomedical Relative Risk vs. Return Landscape

If you would invest  0.20  in Entest Biomedical on November 10, 2025 and sell it today you would lose (0.18) from holding Entest Biomedical or give up 90.0% of portfolio value over 90 days. Entest Biomedical is currently does not generate positive expected returns and assumes 11.1631% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Entest, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon.
  Expected Return   
       Risk  
Given the investment horizon of 90 days Entest Biomedical is expected to under-perform the market. In addition to that, the company is 13.74 times more volatile than its market benchmark. It trades about -0.12 of its total potential returns per unit of risk. The Dow Jones Industrial is currently generating roughly 0.12 per unit of volatility.

Entest Biomedical Target Price Odds to finish over Current Price

The tendency of Entest Pink Sheet price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to move above the current price in 90 days
 0.0002 90 days 0.0002 
about 58.59
Based on a normal probability distribution, the odds of Entest Biomedical to move above the current price in 90 days from now is about 58.59 (This Entest Biomedical probability density function shows the probability of Entest Pink Sheet to fall within a particular range of prices over 90 days) .
Given the investment horizon of 90 days the pink sheet has the beta coefficient of 1.99 suggesting as the benchmark fluctuates upward, the company is expected to outperform it on average. However, if the benchmark returns are projected to be negative, Entest Biomedical will likely underperform. Additionally Entest Biomedical has a negative alpha, implying that the risk taken by holding this instrument is not justified. The company is significantly underperforming the Dow Jones Industrial.
   Entest Biomedical Price Density   
       Price  

Predictive Modules for Entest Biomedical

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Entest Biomedical. Regardless of method or technology, however, to accurately forecast the pink sheet market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the pink sheet market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Hype
Prediction
LowEstimatedHigh
0.000.000211.16
Details
Intrinsic
Valuation
LowRealHigh
0.000.000211.16
Details

Entest Biomedical Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Entest Biomedical is not an exception. The market had few large corrections towards the Entest Biomedical's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Entest Biomedical, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Entest Biomedical within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
-1.53
β
Beta against Dow Jones1.99
σ
Overall volatility
0.0004
Ir
Information ratio -0.13

Entest Biomedical Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Entest Biomedical for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Entest Biomedical can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Entest Biomedical generated a negative expected return over the last 90 days
Entest Biomedical has high historical volatility and very poor performance
Entest Biomedical has some characteristics of a very speculative penny stock
Entest Biomedical has high likelihood to experience some financial distress in the next 2 years
Entest Biomedical currently holds 38.29 K in liabilities with Debt to Equity (D/E) ratio of 27.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Entest Biomedical has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Entest Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Entest Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entest Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entest to invest in growth at high rates of return. When we think about Entest Biomedical's use of debt, we should always consider it together with cash and equity.
Entest Biomedical currently holds about 423.97 K in cash with (3.96 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.

Entest Biomedical Fundamentals Growth

Entest Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Entest Biomedical, and Entest Biomedical fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Entest Pink Sheet performance.

About Entest Biomedical Performance

By evaluating Entest Biomedical's fundamental ratios, stakeholders can gain valuable insights into Entest Biomedical's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Entest Biomedical has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Entest Biomedical has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
It intends to seek business opportunities to review and analyze for purposes of effecting a merger, acquisition, or other business combination with an operating company business. Entest Group, Inc. was founded in 2008 and is based in Shenzhen, China. Entest is traded on OTC Exchange in the United States.

Things to note about Entest Biomedical performance evaluation

Checking the ongoing alerts about Entest Biomedical for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Entest Biomedical help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Entest Biomedical generated a negative expected return over the last 90 days
Entest Biomedical has high historical volatility and very poor performance
Entest Biomedical has some characteristics of a very speculative penny stock
Entest Biomedical has high likelihood to experience some financial distress in the next 2 years
Entest Biomedical currently holds 38.29 K in liabilities with Debt to Equity (D/E) ratio of 27.3, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Entest Biomedical has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Entest Biomedical until it has trouble settling it off, either with new capital or with free cash flow. So, Entest Biomedical's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Entest Biomedical sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Entest to invest in growth at high rates of return. When we think about Entest Biomedical's use of debt, we should always consider it together with cash and equity.
Entest Biomedical currently holds about 423.97 K in cash with (3.96 K) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.01, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Evaluating Entest Biomedical's performance can involve analyzing a variety of financial metrics and factors. Some of the key considerations to evaluate Entest Biomedical's pink sheet performance include:
  • Analyzing Entest Biomedical's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
  • Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Entest Biomedical's stock is overvalued or undervalued compared to its peers.
  • Examining Entest Biomedical's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
  • Evaluating Entest Biomedical's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Entest Biomedical's management team can help you assess the Company's leadership.
  • Pay attention to analyst opinions and ratings of Entest Biomedical's pink sheet. These opinions can provide insight into Entest Biomedical's potential for growth and whether the stock is currently undervalued or overvalued.
It's essential to remember that evaluating Entest Biomedical's pink sheet performance is not an exact science, and many factors can impact Entest Biomedical's pink sheet market price. Therefore, it's also important to diversify your portfolio and not rely solely on one company or stock for your investments.

Complementary Tools for Entest Pink Sheet analysis

When running Entest Biomedical's price analysis, check to measure Entest Biomedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Entest Biomedical is operating at the current time. Most of Entest Biomedical's value examination focuses on studying past and present price action to predict the probability of Entest Biomedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Entest Biomedical's price. Additionally, you may evaluate how the addition of Entest Biomedical to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Equity Valuation
Check real value of public entities based on technical and fundamental data
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
AI Portfolio Prophet
Use AI to generate optimal portfolios and find profitable investment opportunities
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Transaction History
View history of all your transactions and understand their impact on performance